Literature DB >> 17905520

Activation of fibroblast growth factor receptor by axotomy, through downstream p38 in dorsal root ganglion, contributes to neuropathic pain.

H Yamanaka1, K Obata, K Kobayashi, Y Dai, T Fukuoka, K Noguchi.   

Abstract

The possible involvement of fibroblast growth factor receptor (FGFR) activation in the dorsal root ganglion (DRG) was examined following peripheral nerve injury in the rat. Ligation of the sciatic nerve down-regulated FGFR2, -3 and -4 mRNA; however, the expression of FGFR1 mRNA showed no change. Activation of FGFR was examined by immunohistochemistry using an antibody of the phosphorylated form of FGFR1-4. Ligation of the sciatic nerve produced phosphorylation of FGFR in the L4 and 5 DRG ipsilateral to the injury, starting at 3 days after the lesion and persisting for more than 30 days. Substantial activation of FGFR was observed, mainly in unmyelinated small DRG neurons that co-expressed phosphorylated p38 mitogen-activated protein kinase (MAPK). Continuous intrathecal infusion of the FGFR1 inhibitor, 3-[3-(2-carboxyethyl)-4-methylpyrrol-2-methylidenyl]-2-indolinone, reduced p38 MAPK phosphorylation in the DRG and pain-related behaviors in the partial sciatic nerve model rat without affecting on the activation of spinal glia cells (microglia and astrocyte). In the injured small DRG neurons, activation of FGFR1 may contribute to the generation of neuropathic pain by activating p38 MAPK.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17905520     DOI: 10.1016/j.neuroscience.2007.08.024

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  8 in total

1.  Spinal astrocytic FGFR3 activation leads to mechanical hypersensitivity by increased TNF-α in spared nerve injury.

Authors:  Ke-Yu Xie; Qiang Wang; De-Jun Cao; Jia Liu; Xian-Feng Xie
Journal:  Int J Clin Exp Pathol       Date:  2019-08-01

2.  Inhibition of fibroblast growth factor receptor 1: influence on tympanic membrane wound healing in rats.

Authors:  Holger Kaftan; Lars Reuther; Bärbel Miehe; Werner Hosemann; Achim Beule
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-05-18       Impact factor: 2.503

3.  FGF23, Frailty, and Falls in SPRINT.

Authors:  Anna Jovanovich; Charles Ginsberg; Zhiying You; Ronit Katz; Walter T Ambrosius; Dan Berlowitz; Alfred K Cheung; Monique Cho; Alexandra K Lee; Henry Punzi; Shakaib Rehman; Christianne Roumie; Mark A Supiano; Clinton B Wright; Michael Shlipak; Joachim H Ix; Michel Chonchol
Journal:  J Am Geriatr Soc       Date:  2020-12-01       Impact factor: 5.562

Review 4.  Fibroblast Growth Factor Signalling in the Diseased Nervous System.

Authors:  Lars Klimaschewski; Peter Claus
Journal:  Mol Neurobiol       Date:  2021-04-15       Impact factor: 5.590

5.  Inhibition of spinal MAPKs by scorpion venom peptide BmK AGAP produces a sensory-specific analgesic effect.

Authors:  Jia-Ping Ruan; Qing-Hong Mao; Wu-Guang Lu; Xue-Ting Cai; Jiao Chen; Qing- Li; Qun- Fu; Huai-Jiang Yan; Jun-Li Cao; Peng Cao
Journal:  Mol Pain       Date:  2018-02-09       Impact factor: 3.395

6.  Differential expression of mGluRs in rat spinal dorsal horns and their modulatory effects on nocifensive behaviors.

Authors:  Masamichi Okubo; Hiroki Yamanaka; Kimiko Kobayashi; Koichi Noguchi
Journal:  Mol Pain       Date:  2019 Jan-Dec       Impact factor: 3.395

7.  A ligand-receptor interactome platform for discovery of pain mechanisms and therapeutic targets.

Authors:  Andi Wangzhou; Candler Paige; Sanjay V Neerukonda; Dhananjay K Naik; Moeno Kume; Eric T David; Gregory Dussor; Pradipta R Ray; Theodore J Price
Journal:  Sci Signal       Date:  2021-03-16       Impact factor: 8.192

8.  Differential activation of p38 and extracellular signal-regulated kinase in spinal cord in a model of bee venom-induced inflammation and hyperalgesia.

Authors:  Xiu-Yu Cui; Yi Dai; Sheng-Lan Wang; Hiroki Yamanaka; Kimiko Kobayashi; Koichi Obata; Jun Chen; Koichi Noguchi
Journal:  Mol Pain       Date:  2008-04-30       Impact factor: 3.395

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.